Home
Storia in 4 fonti
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
- ·
biopharmadive.com
Biogen pushing tau drug forward despite Alzheimer’s study failure
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase…
- ·
statnews.com
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
- ·
endpoints.news
Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but showed other signs of benefit.
- ·
cnbc.com
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.